NAB-001(NAB-001) - _专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [1]

靶点-

作用机制-

治疗领域

感染皮肤和肌肉骨骼疾病

在研适应症-

非在研适应症

甲癣

原研机构

Promius Pharma LLC

在研机构-

非在研机构

Promius Pharma LLC

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 NAB-001 相关的临床试验

NCT01208168 / Terminated临床3期

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Wks

The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.

开始日期2010-09-01

申办/合作机构

Promius Pharma LLC

NCT01208129 / Terminated临床3期

A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Distal Subungual Onychomycosis of the Toenails for 52 Weeks

The objectives of this study are to assess the safety of NAB001 for topical treatment of mild to moderate distal onychomycosis of the toenails over 52 weeks and to compare the efficacy of NAB001 to vehicle alone at the end of the study (Week 56) after treating for 52 weeks.

开始日期2010-09-01

申办/合作机构

Promius Pharma LLC

100 项与 NAB-001 相关的临床结果

登录后查看更多信息

100 项与 NAB-001 相关的转化医学

登录后查看更多信息

100 项与 NAB-001 相关的专利（医药）

登录后查看更多信息

100 项与 NAB-001 相关的药物交易

登录后查看更多信息